SGLT2 inhibitors reduce inflammatory cells linked to heart disease
For the first time in a human trial, a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, already known for their weight loss and glucose lowering benefits, has been shown to also reduce inflammatory cells in the blood known to cause cardiovascular disease.
Read original article on The Medical News →Related news
-
New AI model detects heart transplant rejection without biopsies
United Kingdom
-
Exercise as medicine: How physical activity helps manage chronic disease
United Kingdom
-
Tumor markers reveal which HER2+ breast cancer patients may respond to less intensive chemotherapy
United Kingdom
-
Scientists discover a novel strategy to unmask cancer cells in high-risk neuroblastoma
United Kingdom
-
New review identifies pistachios as a promising whole food for sleep research
United Kingdom
-
New global definition changes how childhood obesity is identified
United Kingdom
-
Inherited lupus can begin early—and continue silently
United Kingdom
-
Study uncovers link between inherited blindness and a gene causing rare metabolic disease
United Kingdom